27 May Verdict Medical Devices: US FDA clears 4DMedical’s lung imaging technology
26 MAY 2020
4DMedical software identifies and quantifies any functional impairment by rapidly and automatically analysing and applying its proprietary algorithms to the X-ray.
Within three hours, the software provides a ventilation report to the hospital, enabling clinicians to choose the most effective treatment and allocate hospital resources.
The company noted that its ventilation reports can deliver quantitative support for Covid-19 diagnosis and follow up examinations for patients with or recovering from Covid-19.
However, XV Technology is not intended to replace molecular tests as the primary diagnosis method for Covid-19.
XV Technology supported by 15 years of preclinical and clinical trials and existing collaborations with hospitals across the world.
Australian government’s Medical Research Future Fund (MRFF) Frontier Health and Medical Research Programme has validated the technology through an extensive vetting process.
Original Article: https://ow.ly/Wc7a50zT7HN